SAN DIEGO and SINGAPORE, July 7, 2015 /PRNewswire/ -- Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development (Covance). Covance will process patient samples in Singapore, and then send samples to Epic's clinical laboratory in San Diego, which has recently been licensed under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, for downstream detection and molecular characterization of CTCs. This agreement expands on a previous contract announced last year between Epic and LabCorp for European clinical trials.
"The expansion of the partnership with LabCorp will provide an important access point for all oncology clinical trials conducted in Asiaand meet the global demand for Epic's circulating tumor cell technology," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. "For Epic's clinical trial partners and customers, we provide significant, actionable information on patient matching, treatment effectiveness and disease progression to streamline clinical trials for new targeted cancer therapies and to develop essential companion diagnostics."
"We are excited to expand access to Epic's circulating tumor cell technology from Europe to Asia," said Dr. Steven M. Anderson, Chief Scientific Officer of Covance Drug Development. "Epic's technology, which can robustly and reproducibly detect, quantitate and molecularly characterize circulating tumor cells, is a significant tool available to support oncology clinical trials."
Epic is developing new, high-definition diagnostic tests to provide clinically relevant information about how a patient's cancer changes over time, which will allow for improved therapy selection and early drug resistance detection. From a simple blood draw, Epic's no cell left behindTM technology analyzes approximately six million cells across more than 90 parameters to capture and analyze all possible types of circulating tumor cells. Unlike other blood-based biomarkers used in liquid biopsies, CTCs hold both genetic and proteomic information and encompass the profiles of both primary tumors and metastases. Epic's technology can incorporate CTC enumeration, quantitative protein biomarker analysis and single-cell genomic analysis by next generation sequencing (NGS) or fluorescent in situ hybridization (FISH) to give a comprehensive picture of a patient's cancer.
LabCorp is the world's leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. With combined revenue proforma for the acquisition of Covance in excess of $8.5 billion in 2014 and more than 48,000 employees in over 60 countries, LabCorp offers innovative solutions to healthcare stakeholders, including physicians, patients and consumers, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and clinical labs.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.